| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 8, 2015 | Tech titans talks climate change and health with Obama, Press Ganey is going public (Morning Read) | Healthcare should watch how life insurance handles managing using personal data to improve its products. The program sounds very familiar to what health insurance and smaller wellness upstarts have offered. It’s worked overseas for life ins... |
| Feb 17, 2011 | Watson: From Jeopardy to healthcare (Morning Read) | An Obamacare waiver. Four states — Florida, New Jersey, Ohio and Tennessee — have received a waiver that lets health insurance companies offer a decreased amount of benefits than outlined in the new healthcare reform law. More states are li... |
| Feb 16, 2011 | Raise the bar on ‘me too’ drugs (Morning Read) | But once a generic becomes available, new drugs in the class would have to show they are superior to existing medicines to win the FDA’s OK.
Sanofi buys Genzyme for $20.1 billion. Via The Associated Press: “Genzyme would give Sanofi a new p... |
| Jan 18, 2011 | Republicans to base healthcare debate reform on jobs | MASSDEVICE ON CALL — Republicans to base healthcare debate reform on jobs. The House will begin debate on the two-page healthcare repeal bill launched by Republicans, after a week-long hiatus following the shooting of Rep. Gabrielle Gifford... |
| Jan 18, 2011 | Global med-tech industry catching up to the United States (Morning Read) | It would be tough for anyone, particularly the many admirers of Jobs and his creations, to hear further details of what he is going through. But a single dose of clear and accurate health data would not be nearly so crushing as the endless ... |
| Jan 7, 2011 | Cleveland Clinic cardiologist fits FDA profile for Sharfstein replacement | He’s a long shot. But Cleveland Clinic cardiologist Dr. Steven Nissen may be exactly what the troubled Food & Drug Administration needs.
Conventional wisdom is that the departure of FDA deputy commissioner Joshua Sharfstein represents a... |
| Jan 6, 2011 | Sharfstein’s FDA replacement: Why not Cleveland Clinic’s Steven Nissen? | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| Jan 5, 2011 | Sharfstein’s departure: Did he cut and run? (Morning read) | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Jan 5, 2011 | Study: One in five defibrillators implanted outside medical guidelines | MassDevice On Call | Study: One in five defibrillators implanted outside medical guidelines. A study published in The Journal of the American Medical Association that reviewed 111,707 defibrillator implants showed that 22.5 percent of patients did not need or f... |
| Sep 23, 2010 | What will Novartis’ multiple sclerosis pill cost? (Morning Read) | Building a better antibody. CytomX Therapeutics in Santa Barbara, California, has bagged $30 million in a Series B led by Third Rock Ventures and joined by Roche Venture Fund to drive several next-generation antibody programs to the clinic,... |
| Jul 23, 2010 | Return of the public option? Don’t bet on it (Morning Read) | Secession in Florida: Florida’s state doctors’ association is considering severing its ties to the American Medical Association over the latter’s support for federal health reform. The secession proposal says the AMA “failed to achieve one ... |
| Jul 12, 2010 | iPhone video chat a ‘game-changing tool’ for doctors (Morning Read) | Who will succeed Tauzin? PhRMA, the trade group representing big drugmakers, is rumored to be ready to announce its new chief, The In Vivo Blog reports, but who could it be? “If PhRMA is ready to make the pick, it will surely be someone wit... |
| Aug 13, 2009 | Turmoil at the FDA? — MedCity Morning Read, Aug. 13, 2009 | Momenta says the co-authored paper represents a conflict of interest and asked that Woodcock excuse herself from the blood thinner approval process. The FDA says it’s aware of the complaint, but Woodcock had not removed herself from the pr... |
| Mar 20, 2009 | MedCity morning read, Friday, March 20 | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| Mar 2, 2009 | MedCity morning read, Monday, March 2 | “We’re in bad shape, very bad shape, and this just confirms it, Mark Zandi, chief economist for Moody’s Economy.com, told the AP. “I think the administration budget is optimistic on growth, especially this year and 2010. I think it will be ... |
| Feb 5, 2009 | MedCity Morning read, Thursday, Feb. 5 | Here are some stories worth a read:
The Next HHS Secretary: All Signs Point to Kansas (IN VIVO Blog)
Heinen’s, Cleveland Clinic team up to identify healthier foods (The Plain Dealer)
Record Year for US Cleantech Investments with $4.7 Billio... |
| Jan 27, 2009 | MedCity morning read, Tuesday, Jan. 27 | Image by Getty Images via Daylife
The Pfizer-Wyeth deal may or may not be good for the two companies. But it seems clear the deal means trouble, in the near term, for smaller biotech companies.
Because of the merger, Wyeth withdrew from tal... |
| Jan 5, 2009 | Hey Life Sciences Fans, Remember The Deals Back in 2008… | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
I recently had coffee with a venture capitalist at the Starbucks across the street from Biogen Idec’s (NASDAQ:BIIB) headquarters in Kendall Square, and he asked me what I thou... |
| Mar 5, 2008 | Precision Thera merger with “blank check” firm Oracle Healthcare collapses | (UPDATED: See below.)
Another one bites the dust.
The saga of Precision Therapeutics, a Pittsburgh biotech developing what struck me last August as a particularly crude type of cancer-chemotherapy diagnostic, continues apace. In a tersely w... |
| Feb 28, 2008 | Life sciences briefing: Thursday, Feb. 28, 2008 | RNAi developer PhaseRx gets $4M of a pledged $19M — Investor interest in RNA interference, an ancient cellular mechanism for silencing dangerous genes, continues apace. PhaseRx, a Seattle biotech, has raised $4 million of a pledged $19 mill... |
| Feb 12, 2008 | Brace yourselves for the SPAC attack | Life-science IPOs may be hitting the wall — so far this year, seven biotech and medical-device startups have yanked their offerings — but one part of the IPO market is booming. That’s the field of “special-purpose acquisition corporations,”... |
| Feb 8, 2008 | Life sciences briefing: Friday, Feb. 8, 2008 | TODAY’S HEADLINES:
AerovectRx takes $1.2M, looks for $5M more for inhaled drugs (VentureWire)
Pointe Conception, endoscopic camera maker, raises $800K (VentureWire)
Orion Healthcare aims for $250 million life-science fund (VentureWire)
Penn... |
| Jan 25, 2008 | Bioroundup: Stem-cell science and money, genetic tests go political, clinical-trial data woes, and more | (NOTE: Apologies — especially to RSS readers — if you’ve seen this post before, but an apparent server error ate it late yesterday and I was only able to recover it this morning. Enjoy, or ignore, as seems most fit.)
Featured stories:
Stem-... |
| Dec 18, 2007 | Biogen Idec-Icahn Story Likely Far From Over; History Says the Activist Investor Will Act Again | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Does anyone really think Carl Icahn is done with Biogen Idec? He pushed for a sale of the company, by most reports at a price around $80 per share. But as of yesterday’s close... |
| Oct 31, 2007 | Life sciences briefing: Wednesday, Oct. 31, 2007 | Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals
UPDATED: Expanded items on Harmony Info, SymBio Pharma and Merrion... |
| Oct 31, 2007 | Bioroundup: Clinical-trial loopholes, newborn genetic testing, “personalized” stem cells, and more | Featured stories:
1. Shortcomings in clinical-trial disclosure
2. Complications of newborn genetic screening
3. Personalized stem cells under fire
4. Health money flows to Democratic presidential hopeful
5. Massachusetts ponders $1B biotech... |
| Sep 24, 2007 | Alnylam and Merck Go Their Separate Ways, TransMedics Files to Go Public, ZipCar Reservation System Ready to Go Anywhere, and More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Another week, another giant inbox full of news. Here are the highlights.
—Not long after closing one of New England’s 10 biggest second-quarter venture deals, Andover-based Tr... |
| Sep 6, 2007 | EPO’s makers may be down, but they’re not out | (UPDATED: See below.)
Erythropoietin, or EPO, and its close relatives didn’t become the world’s most popular biotech drugs — at least through last year, when they pulled in sales of almost $12 billion — for nothing. On the plus side of the ... |
| Aug 23, 2007 | Life sciences briefing: Thursday, Aug. 23, 2007 | (UPDATED at 6:30am PT on Friday: See below.)
Featured companies: DNA2.0, Globus Medical, Inotek Pharmaceuticals, Operon Biotechnologies, PleuraFlow
Globus Medical raises $110M for spinal implants — Globus Medical, an Audubon, Pa., developer... |
| Aug 20, 2007 | Life sciences briefing: Monday, Aug. 20, 2007 | (UPDATED at 7:10pm PT: See below.)
Featured companies: NeurAxon, VytronUS, Avila Therapeutics, CardioNet, Ventana Medical Systems, CytoLogix, PlaCor
NeurAxon raises $32M for pain drugs — You have to hand it to Waltham, Mass.-based NeurAxon ... |
| Aug 16, 2007 | Double vision: Ophthotech, Eyetech and Lux BioSciences | When news that the brand-new startup Ophthotech had raised a $36 million first round broke on Monday, it was clear that the venture amounted to a kind of do-over for officials of the late, unlamented Eyetech Pharmaceuticals. Eyetech, you mi... |
| Aug 14, 2007 | Review of a preview: Google Health | (UPDATED: See below.)
No sooner does the NYT run a significant piece on health-info efforts at Google and Microsoft than someone decides to leak the “preview” of the site to Google Blogoscoped. (Site author Philipp Lenssen confirms that it ... |
| Aug 10, 2007 | Biotech’s double standard on biogenerics | (UPDATED: See below.)
Yesterday, the WSJ Health Blog cited a WSJ story as evidence that “biogenerics” — that is, generic versions of biotech drugs, which currently don’t exist — need to be treated with caution. Unfortunately, that post miss... |
| Aug 8, 2007 | Spinal fusion: Will the Medtronic/Kyphon deal quell ferment in the orthopedic-implant market? | I didn’t write about Medtronics’ $3.9 billion acquisition of Kyphon when it was announced almost two weeks ago, largely because it seemed to be a pretty straightforward merger of two big public companies with relatively few implications for... |
| Jul 20, 2007 | Adimab: A potential one-stop shop for antibodies | Adimab, a Lebanon, N.H., biotech startup developing a “platform” for the discovery and commercialization of yeast-derived antibodies, raised $6 million in a first funding round (hat tips to the In Vivo Blog and VentureWire). The company was... |
| Global med-tech industry catching up to the United States (Morning Read) | Current medical news and unique business news for anyone who cares about the healthcare industry.
American med-tech dominance wanes? PwC’s latest Medical Technology Innovation Scorecard says the United States’ med-tech industry is losing gr... |
| Raise the bar on ‘me too’ drugs (Morning Read) | Current medical news and unique business news for anyone who cares about the healthcare industry.
A high standard for ‘me too’ drugs. A new suggestion would make it harder for me-too drugs, particularly when there’s a generic version, to wi... |
| What will Novartis’ multiple sclerosis pill cost? (Morning Read) | Highlights of the important and interesting in the world of healthcare:
What cost, Gilenya? Swiss drugmaker Novartis just got Food and Drug Administration approval to sell the first pill that can slow the progression of multiple sclerosis. ... |
| MedCity Morning read, Thursday, Feb. 5 | We’d be remiss if we didn’t mention tonight is the launch party for the start of MedCity News. We’ll be serving food and drinks and celebrating the start of our medical industry news service (and, as a nice bonus, online radio host Doctor A... |
| Sharfstein’s FDA replacement: Why not Cleveland Clinic’s Steven Nissen? | He’s a long shot. But Cleveland Clinic cardiologist Dr. Steven Nissen may be exactly what the troubled U.S. Food and Drug Administration needs.
Conventional wisdom is that the departure of FDA Deputy Commissioner Joshua Sharfstein represent... |
| Return of the public option? Don’t bet on it (Morning Read) | Highlights of the important and the interesting from the world of healthcare:
Return of the public option? Don’t bet on it: Nearly 130 House Democrats are pushing to restore the once-proposed “public option“–essentially a government-run hea... |
| iPhone video chat a ‘game-changing tool’ for doctors (Morning Read) | Highlights of the important and the interesting from the world of healthcare:
iPhone video chat a “game-changing tool” for doctors: Two doctors participated in what may be the first documented medical consultation conducted via the iPhone’s... |
| Watson: From Jeopardy to healthcare (Morning Read) | Current medical news and unique business news for anyone who cares about the healthcare industry.
What can’t Watson do? After kicking butt on Jeopardy it looks like the artificial intelligence Watson may have a chance to change healthcare. ... |
| MedCity morning read, Friday, March 20 | It turns out that you can doubt God’s work.
That would be if God were Dr. Joseph Biederman, the Harvard child psychiatrist under scrutiny for encouraging the use of antipsychotic drugs in children and potential conflicts with drug companies... |
| Sharfstein’s departure: Did he cut and run? (Morning read) | Current medical news and unique business news for anyone that cares about the healthcare industry.
Strategy behind Sharfstein. InVivo blog on FDA Deputy Commissioner Joshua Sharfstein’s departure: “Sharfstein’s departure means first and for... |
| Third Rock Ventures closes $616 million healthcare fund | Third Rock Ventures announced Monday that it had closed its fourth fund — it’s largest, Third Rock Ventures IV — for an oversubscribed $616 million.
The Boston, Massachusetts-based firm now has a total of $1.9 billion in assets under manage... |
| MedCity morning read, Monday, March 2 | President Barack Obama may have been too optimistic about economic recovery in the $3.6 trillion federal budget he announced last week, according to an analysis by Associated Press writer Tom Raum.
The president’s ambitious plans for a ... |
| Turmoil at the FDA? — MedCity Morning Read, Aug. 13, 2009 | WASHINGTON, D.C. — The inspector general of the U.S. Department of Health and Human Services is investigating a conflict-of-interest allegation involving the nation’s top drug regulator, Janet Woodcock, according to the U.S. Food and Drug A... |
| Tech titans talks climate change and health with Obama, Press Ganey is going public (Morning Read) | TOP STORIES
The Obama administration is expressing concern about how climate change is affecting health. At Howard University Medical School the president announced that Google, Microsoft and others have committed to help in preparation for... |